Skip to main content
. 2016 Aug 30;51(3):217–226. doi: 10.1007/s13139-016-0446-5

Fig. 7.

Fig. 7

A 72-year-old woman with an invasive carcinoma. Baseline FDG PET (a) and FDG/ADC PET/MR mammography (b). After the first cycle of neoadjuvant chemotherapy, a significant reduction in tumor FDG uptake from an SUVmax of 13.8 to an SUVmax of 6.4 without a change in the ADC is seen on FDG PET (c) and FDG/ADC PET/MR mammography (d). Histopathology at completion of chemotherapy showed no residual disease in the tumor bed